Phosphodiesterase (PDE) Inhibitors Market Size & Share, by Drug Class {Selective PDE Inhibitors (PDE-1, PDE-2, PDE-3, PDE-4, PDE-5) and Non-Selective PDE Inhibitors}; Type (Oral, Typical) and By Application (Respiratory Disease, Erectile Dysfunction, Vascular Disease, Diabetes) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

Growth Drivers

Rising Prevalence Of Chronic Disease And Erectile Dysfunction

The phosphodiesterase (PDE) inhibitors market is estimated to witness robust growth on account of the growing concern for the chronic diseases such as heart disease, stroke, diabetes, and prediabetes amongst individuals worldwide, which is raising the need for the treatment of the diseases. Further, increasing expenditure for the treatment of such chronic diseases is also anticipated to drive the growth of the market. According to the World Health Organization, 17.9 million people die each year from cardiovascular disease, an estimated 31% of all death worldwide. Moreover, escalating the prevalence of erectile dysfunction multiple factors, such as diabetes mellitus, testosterone deficiency, prostate cancer, obesity, hypertension, and hyperlipidemia are estimated to support the development of the global market. Furthermore, rapid urbanization and the inherent lifestyle changes, along with high stress at the workplace are rendering young men more susceptible to erectile dysfunction.

Restraints

Potent Drug Interaction of Phosphodiesterase (PDE) inhibitors

The global phosphodiesterase (PDE) inhibitors market is anticipated to hampered by factors such as potential drug interactions of PDE inhibitors, side-effects associated with PDE inhibitors, and the launch of generics.